Synopsys, Inc. $SNPS Stock Sold by Edgewood Management LLC

Edgewood Management LLC decreased its holdings in shares of Synopsys, Inc. (NASDAQ:SNPS – Free Report) by 45.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 665,184 shares of the semiconductor company’s stock after selling 562,780 shares during the quarter. Synopsys accounts for approximately 4.6% of Edgewood Management LLC’s portfolio, making the stock its 9th largest position. Edgewood Management LLC’s holdings in Synopsys were worth $289,315,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the stock. Elevation Wealth Partners LLC increased its stake in Synopsys by 96.4% in the second quarter. Elevation Wealth Partners LLC now owns 55 shares of the semiconductor company’s stock valued at $25,000 after acquiring an additional 27 shares during the last quarter. Osbon Capital Management LLC purchased a new stake in Synopsys during the second quarter valued at about $25,000. IMG Wealth Management Inc. bought a new stake in Synopsys during the second quarter worth about $28,000. GK Wealth Management LLC bought a new stake in Synopsys during the third quarter worth about $28,000. Finally, EFG International AG purchased a new position in shares of Synopsys in the 2nd quarter worth about $34,000. 85.47% of the stock is currently owned by institutional investors.

Synopsys Trading Down 8.0%

NASDAQ SNPS opened at $396.55 on Friday. Synopsys, Inc. has a 1-year low of $362.55 and a 1-year high of $539.48. The company has a current ratio of 1.34, a quick ratio of 1.24 and a debt-to-equity ratio of 0.29. The stock has a 50-day moving average of $448.46 and a 200-day moving average of $440.14. The firm has a market cap of $76.00 billion, a PE ratio of 70.06, a price-to-earnings-growth ratio of 1.40 and a beta of 1.18.

Synopsys (NASDAQ:SNPS – Get Free Report) last announced its quarterly earnings results on Wednesday, August 26th. The semiconductor company reported $3.91 EPS for the quarter, topping analysts’ consensus estimates of $3.67 by $0.24. The business had revenue of $2.48 billion for the quarter, compared to analysts’ expectations of $2.44 billion. Synopsys had a return on equity of 6.24% and a net margin of 11.43%. The business’s quarterly revenue was up 42.4% on a year-over-year basis. During the same period in the previous year, the firm earned $3.39 EPS. Synopsys has set its Q4 2026 guidance at 4.100-4.160 EPS and its FY 2026 guidance at 15.040-15.100 EPS. As a group, sell-side analysts forecast that Synopsys, Inc. will post 11.01 EPS for the current year.

Synopsys declared that its board has authorized a share repurchase program on Monday, October 5th that permits the company to buy back $1 billion in outstanding shares. This buyback authorization permits the semiconductor company to repurchase up to 1.1% of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s board believes its stock is undervalued.

Insider Activity

In other news, insider Janet Lee sold 1,144 shares of Synopsys stock in a transaction that occurred on Tuesday, October 6th. The stock was sold at an average price of $502.52, for a total value of $574,882.88. Following the sale, the insider directly owned 16,534 shares in the company, valued at approximately $8,308,665.68. This trade represents a 6.47% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Sassine Ghazi sold 14,604 shares of the company’s stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $462.84, for a total value of $6,759,315.36. Following the transaction, the chief executive officer owned 76,865 shares of the company’s stock, valued at approximately $35,576,196.60. This represents a 15.97% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 117,163 shares of company stock worth $51,366,457 in the last quarter. Insiders own 0.56% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Wells Fargo & Company increased their price objective on Synopsys from $475.00 to $540.00 and gave the company an “overweight” rating in a research report on Thursday, October 1st. Deutsche Bank restated a “buy” rating and issued a $640.00 target price (up from $590.00) on shares of Synopsys in a research report on Thursday, October 1st. BNP Paribas Exane upped their target price on Synopsys from $420.00 to $475.00 and gave the stock a “neutral” rating in a research note on Thursday, October 1st. Robert W. Baird upgraded shares of Synopsys from a “neutral” rating to an “outperform” rating and increased their price target for the company from $558.00 to $560.00 in a research report on Thursday, August 27th. Finally, HSBC downgraded shares of Synopsys from a “buy” rating to a “reduce” rating in a research note on Friday, September 25th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $577.71.

View Our Latest Research Report on SNPS

Key Stories Impacting Synopsys

Investors following SNPS have been watching these stories:

  • Positive Sentiment: Synopsys-backed Ansys is supporting an integration between Instem’s toxicology tools and its simulation platform, extending the company’s reach into packaging safety and materials-risk workflows. This could broaden use of its simulation ecosystem, though the financial impact is not specified. Synopsys broadens platform reach
  • Neutral Sentiment: Synopsys is described as having stronger forward growth and a lower forward valuation multiple than Cadence, but Cadence is credited with a stronger balance sheet and returns on capital. Synopsys vs. Cadence
  • Negative Sentiment: A valuation analysis argues SNPS may be about 17% overvalued despite improving guidance and business performance, raising questions about whether future cash generation justifies the share price. Synopsys may be overvalued

Synopsys Company Profile

(Free Report)

Synopsys, Inc. develops software, semiconductor intellectual property (IP) and services used to design and verify electronic systems. Its electronic design automation (EDA) tools help customers create, simulate, test and validate chips and other complex electronic products, while its IP portfolio provides reusable building blocks for semiconductor designs. The company also offers software security and quality tools that help developers identify vulnerabilities and assess applications throughout the software development process.

Recommended Stories

Want to see what other hedge funds are holding SNPS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Synopsys, Inc. (NASDAQ:SNPS – Free Report).

Institutional Ownership by Quarter for Synopsys (NASDAQ:SNPS)

Receive News & Ratings for Synopsys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synopsys and related companies with MarketBeat.com's FREE daily email newsletter.